<DOC>
	<DOCNO>NCT01039194</DOCNO>
	<brief_summary>The purpose study find plasma concentration galantamine extend release change BMS-708163 administered time .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Effect BMS-708163 Pharmacokinetics ( PK ) Galantamine Extended Release ( ER )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Healthy men postmenopausal woman Gastrointestinal disorder Bleeding disorder Peptic ulcer disease Cholecystectomy Seizure disorder Asthma Chronic obstructive pulmonary disease Urinary tract obstruction Cardiac conduction abnormality , include limited `` sick sinus syndrome '' unexplained syncopal episode Inability tolerate oral medication Inability venipunctured and/or tolerate venous access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>